Key result
Omitting invasive ischemic evaluation in new-onset post-MI HFrEF is linked to ~67% higher mortality.
Why the study?
Early invasive ischemic evaluation is recommended for the high-risk population with new-onset HF after MI, yet referral rates remain suboptimal, suggesting a potential care gap. This study evaluated the proportion of patients receiving invasive ischemic evaluation after hospitalization for post-MI new-onset systolic HF and its association with mortality.
Does invasive ischemic evaluation with coronary angiography reduce all-cause and cardiovascular mortality in patients with new-onset heart failure with reduced ejection fraction after myocardial infarction?
Cohort (n=257)
No
Does invasive ischemic evaluation with coronary angiography reduce all-cause and cardiovascular mortality in patients with new-onset heart failure with reduced ejection fraction after myocardial infarction?
In patients developing new-onset HFrEF after myocardial infarction, omitting invasive ischemic evaluation was independently associated with significantly higher long-term all-cause and cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
Omitting invasive evaluation was associated with higher mortality in post-MI HFrEF; supports guidelines but leaves open need for randomized confirmation.
Background New-onset heart failure (HF) after myocardial infarction (MI) identifies a high-risk population with increased morbidity and mortality, for whom early invasive ischemic evaluation is recommended. However, referral rates remain suboptimal, suggesting a potential care gap. Objective Evaluate the proportion of patients who underwent invasive ischemic evaluation after hospitalisation for new-onset systolic HF following MI, and to assess its association with all-cause and cardiovascular mortality in a medium-income peripheral hospital. Methods This retrospective cohort study (2000–2019) included 1,720 patients with myocardial infarction (all with coronary obstruction ≥70% on angiography). We identified those who were subsequently admitted with HF with reduced ejection fraction (HFrEF; EF ≤40%) of recent onset and followed them prospectively for a median of 7.6±6.7 years. Patients were stratified by receipt of invasive ischemic evaluation (IE). Cox regression, adjusted for confounding (sex, age, diabetes, smoking, dyslipidemia, hypertension, obesity, sedentary lifestyle, and chronic kidney disease estimated by glomerular filtration rate (GFR)), assessed the independent association with all-cause mortality and cardiovascular mortality. Kaplan-Meier curves assessed survival. Results Of 1,720 MI patients, 257 (15%) developed HFrEF. Among them, 146 (56.8%) underwent invasive IE. Absence of IE and diabetes were independently associated with higher all-cause and cardiovascular mortality. Patients without Ischemic evaluation (IE) had increased all-cause mortality (HR=1.67; 95% CI 1.21–2.29; p=0.002) and cardiovascular mortality (HR=1.55; 95% CI 1.11–2.17; p=0.009). Diabetes was also associated with higher all-cause mortality (HR=1.49; 95% CI 1.11–2.01; p=0.008) and cardiovascular mortality (HR=1.50; 95% CI 1.11–2.06; p=0.012). At approximately 12 years, patients without IE had higher all-cause (71.1% vs 47.9%) and cardiovascular mortality (65.1% vs 45.4%). Conclusion Patients admitted with heart failure with reduced ejection fraction of recent onset after myocardial infarction (MI) remain at high risk of long-term mortality. Early ischemic evaluation with coronary angiography was associated with lower all-cause mortality, cardiovascular death, and HF readmissions by improving residual obstructive disease and reducing progression of heart failure.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2026) conducted a cohort in New-onset heart failure with reduced ejection fraction (HFrEF) after myocardial infarction (n=257). Absence of invasive ischemic evaluation (IE) vs. Receipt of invasive ischemic evaluation (IE) was evaluated on All-cause mortality (HR 1.67, 95% CI 1.21-2.29, p=0.002). Absence of invasive ischemic evaluation in new-onset post-MI HFrEF was associated with higher all-cause (HR 1.67; 95% CI 1.21-2.29; p=0.002) and cardiovascular mortality (HR 1.55; p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: